Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
NEWARK, Calif., Aug. 28, 2017 -- Depomed Inc. (NASDAQ:DEPO) today announced that it has been selected to join the Collaborative for Effective Prescription Opioid Policies (CEPOP) a diverse group of over 70 stakeholders creating and advancing policies and educational initiatives aimed at reducing opioid abuse and promoting treatment options for those living with pain or confronting addiction.
“We are pleased to be joining a well-respected organization that shares our commitment to reducing prescription opioid misuse as well as highlighting the ethical and responsible prescribing and use of treatment options for those living with pain,” said Arthur Higgins, President and Chief Executive Officer of Depomed. “We look forward to engaging with this unique group of patient, family advocacy, public health, prescriber, research and supply chain organizations to develop and implement strategies to address responsible opioid use while recognizing the needs of patients in pain. At Depomed, it is clear to us that tackling these issues requires collaboration among all stakeholders, and we view this partnership with CEPOP as an important addition to our ongoing and future activities aimed at highlighting the responsible prescribing and use of opioids.”
About the Collaborative for Effective Prescription Opioid Policies (CEPOP)
Launched in January of 2015, the Collaborative for Effective Prescription Opioid Policies (CEPOP) brings together a broad array of stakeholders interested in reducing opioid medication abuse, misuse, and diversion. Specifically, CEPOP supports a comprehensive and balanced public policy agenda that reduces abuse and promotes treatment options, both for those living with pain and confronting addiction. CEPOP’s advocacy is focused on driving actions in the public sector that develop and deploy evidence-based solutions to these challenges. For more information visit https://cepoponline.org/
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
